After showing that miR-181b targeted Sema3A to mediate TGF-β–induced EndMT and atrial subendocardial fibrosis in vitro and in vivo, we aimed to evaluate whether miR-181b or Sema3A is a potential therapeutic target for reducing atrial fibrosis and AF vulnerability. This evidence concerns the gene SEMA3A and atrial fibrillation.